Refine your search
Collections
Co-Authors
Journals
- Research Journal of Animal Husbandry & Dairy Science
- International Journal of Science, Engineering and Computer Technology
- Indian Journal of Public Health Research & Development
- Journal of Intellectual Property Rights
- Current Science
- Journal of Scientific and Technical Research (Sharda University, Noida)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Singh, Amit
- Factors Influencing Self-Help Group Members for Selecting Livestock Rearing as an Income Generating Activity
Abstract Views :353 |
PDF Views:2
Authors
Amit Singh
1,
S. Ramkumar
1
Affiliations
1 Department of Veterinary and Animal Husbandry Extension, Rajiv Gandhi Institute of Veterinary Education and Research, Kurumbapet (Puducherry), IN
1 Department of Veterinary and Animal Husbandry Extension, Rajiv Gandhi Institute of Veterinary Education and Research, Kurumbapet (Puducherry), IN
Source
Research Journal of Animal Husbandry & Dairy Science, Vol 5, No 2 (2014), Pagination: 84-87Abstract
A study on Self-help groups (SHGs) was carried out in Durg district of Chhattisgarh State to highlight the socio-economic status of the SHGs members, to investigate the various Income generating activities taken by the SHG members and to identify the reason for selecting livestock as a major source for income. The study shows that majority of the group opting for livestock rearing that to for goat, poultry and dairy rearing. Thus three SHGs each from goat farming, dairy farming and poultry farming IGAs were selected and all the 36 members belonging to these SHGs formed the respondents of the study. The information was collected through semi structured interview schedule, group discussion and through personal interview. In addition, the SHGs with livestock rearing as IGA in Durg were involved in-group farming rather than individual farming. The SHGs were considered as ATM (any time money) by the members to meet their daily expenses, festival expenses expenditures, which include agricultural operations. The SHGs opted for livestock enterprises mainly because they want to improve their economic status, want to get additional income, advice of the officials and availability of the grazing land.Keywords
Income Generating Activity (IGA), Livestock, Livelihood, Self-Help Group.
References
- Annual report (2011-12). Department of Animal Husbandry, Dairying & Fisheries, Ministry of Agriculture, Government of India, NEW DELHI (INDIA).
- DRDA Report (2011-12). DRDA (District Rural Development Agency) Annual report of Durg district. Government of Chhattisgarh, (C.G.).
- Gangaiah, C. Nagaraja, B. and Vasudevulu, C. (2006). Impact of Self-help groups on income and employement: a case study. Kurukshetra, 54(5) : 18-23.
- Jakimow Tanya and Kilby Patrick (2006). Empowering women: A critique of the Blueprint for Self-help groups in India. Indian J. Gender Studies, 13 : 3.
- NABARD (1995). Linking self-help groups with Banks. An Indian Experience, Bombay (M.S.) India.
- Pradan (2005). Social and economic impact of Pradan's SHG microfinance and livelihoods promotion programme. Working paper no. 11 in improving the impact of microfinance on poverty.
- Sharma, Preeti and Varma, Shashi Kanta (2008). Women empowerment through entrepreneurial activities of self-help groups. Indian Res. J. Ext. Edu., 8(1) : 46-51.
- Ramkumar, S. and Rao, S.V.N. (2002). Cattle rearing as a livelihood activity of the landless in Pondicherry In Ramkumar S, Garforth Chris, Rao S.V.N and Waldie Kevin. (eds). Landless Livestock Farming; Problems and prospects. Proceedings of the WorkShop held at RAGACOVAS, Pondicherry.
- Rangnekar, D.V. (2006). Livestock in the livelihoods of the underprivileged communities in India: A review. International Livestock research Institute, Nairobi, Kenya.
- Rao, S.V.N. and Ramkumar, S. (2005). Landless dairy farming- issues and challenges. Dairy Industry Conf. Souvenir IDA Banglore, 34 : 62-67.
- Colour Control Solutions for Offset Printing Industry Using GMI:A Case Study of Manohar Filaments Private Limited, Sonipat
Abstract Views :183 |
PDF Views:2
Authors
Affiliations
1 Somany Institute of Technology and Management, Rewari, Haryana, IN
2 Sterling Publishers Pvt Ltd., Greater Noida, IN
1 Somany Institute of Technology and Management, Rewari, Haryana, IN
2 Sterling Publishers Pvt Ltd., Greater Noida, IN
Source
International Journal of Science, Engineering and Computer Technology, Vol 7, No 1 (2017), Pagination: 47-53Abstract
Aim of this paper is to examine the utilities and applications of GMI (Graphic Measures International) for Colour management solution in Sheet-Fed offset printing industry. GMI is quite new in the field of colour management world and examining its applications will be quite informative and beneficial for all printers and customers as well as. Offset industry need to be standardized for wide range of customer acceptance. A number of print jobs were taken into consideration to examine the facilities provided by GMI colour solutions and how it can be beneficial for printers for long run.Keywords
Colour Standardization, GMI, Colour Matching, Solid Ink Density, Dot Gain, TVI, Colour Difference (ΔE).- Prevalence of Dengu Fever in India along with its Prevention and Treatment By Herbal Medicine
Abstract Views :509 |
PDF Views:0
Authors
Affiliations
1 Professor, Department of Kaumarbhritya, Bal-Roga, Sardar Patel Institute of Ayurvedic Medical Sciences & Research Centre. Lucknow, Uttar Pradesh, IN
2 Assistant Professor, Department of Shalya Tantra, Main Campus Uttarakhand Ayurved University, Harrawala, Dehradun (Uttarakhand), IN
3 Associate Professor, Department of Dravyaguna, Apex Institute of Ayurvedic Medical Sciences, Varanasi, IN
1 Professor, Department of Kaumarbhritya, Bal-Roga, Sardar Patel Institute of Ayurvedic Medical Sciences & Research Centre. Lucknow, Uttar Pradesh, IN
2 Assistant Professor, Department of Shalya Tantra, Main Campus Uttarakhand Ayurved University, Harrawala, Dehradun (Uttarakhand), IN
3 Associate Professor, Department of Dravyaguna, Apex Institute of Ayurvedic Medical Sciences, Varanasi, IN
Source
Indian Journal of Public Health Research & Development, Vol 11, No 2 (2020), Pagination: 323-327Abstract
Background: Dengue viruses are the causative organism of dengue fever (DF) and dengue hemorrhagic fever (DHF). Dengue virus belongs to family Flaviviridae. Dengue virus has four serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) that spread by the bite of infected Aedes Aegypti mosquitoes. In Ayurvedic perspectives, Dengue fever comes under the group of Abhishangaja Jvara. Dengue fever can be controlled and prevented by the number of herbal drugs which is free from any side effects. Main aim of this article is to elaborate the dengue fever and its incidence in India along with review herbal drugs which is effective in prevention and treatment of dengue fever.
Materials and Method: This review work was carried out by using a widespread and planned data mining approach. To achieve significant literature author uses the key words“dengue fever ” “dengue fever in India” and “herbal medicine for Dengue fever”searched in Google Scholar, web of science, Science direct, Scopus, Medline and PubMed Central journal literature.
Results: Seven publications were included in the final selection after systematic analysis.
Conclusion: Dengue is endemic in more than 128 countries; about half of the world’s populations are at risk for infection. It is suggested that herbal plants could be used for prevention and treatment of dengue fever as potential anti-DENV agents and increasing the platelet (PLT) count, white blood cells (WBC) etc.Some herbal extracts have ovicidal activity against Ae. Aegypti.
Keywords
Dengue Fever, India, Herbal Drugs, Abhishangaja Jarav.- Pharmaceutical Test Data Protection and Demands for Data-Exclusivity: Issues and Concerns of Developing Countries and India’s Position
Abstract Views :145 |
PDF Views:101
Authors
Affiliations
1 School of Law, University of Petroleum and Energy Studies (UPES), Bidholi, Dehradun, Uttarakhand - 248 007, IN
1 School of Law, University of Petroleum and Energy Studies (UPES), Bidholi, Dehradun, Uttarakhand - 248 007, IN
Source
Journal of Intellectual Property Rights, Vol 24, No 3&4 (2019), Pagination: 69-88Abstract
Data-exclusivity is one of the most controversial issues in the current discussion on pharmaceutical intellectual property policy-making globally. It is aimed at protecting and safeguarding pharmaceutical test data submitted by pharmaceutical companies to drug regulatory authorities (DRA) for the purpose of obtaining marketing approval for new drugs. Most countries require the submission of test data relating to the efficacy and safety of pharmaceuticals and agro-chemicals as a condition for grant of marketing approval. Since the marketing approval process is laborious and expensive, the originators of such regulatory data demand protection for their investments through exclusivity periods, separate from any patent protection for the active ingredient. On the other hand, generic manufacturers advocate minimal protection for such data as they would be able to obtain speedier marketing approvals. Data-exclusivity thus, prevents during a set period of time, a second pharmaceutical applicant from obtaining a marketing authorization for its drug through a facilitated procedure; this procedure entails reliance by the second applicant on preclinical and clinical data generated by a pioneer company that prepared that data to support its own new drug application. The underlying logic of data-exclusivity suggests that it is an expression of trade-secrets, and that as such, data-exclusivity should be independent of patents. Compared with patents, the market power of data-exclusivity is, in theory, less restrictive, mainly because it does not legally prevent other companies from generating their own registration data. However, in practice, the vast financial resources and extended time required for gathering and generating pharmaceutical registration data for a new drug create a market barrier that is too high for generic based companies.Keywords
TRIPS, Drugs and Cosmetics Act (DCA), 1940,Trans-Pacific Partnership (TPP) Agreement, European Union Data-exclusivity Union, 2005, Data-Exclusivity, Drug Regulatory Authority, Pharmaceutical Patents, Test Data Protection, Research And Development, New Chemical Entities.Full Text
References
- OPPI Position Paper: Regulatory Data Protection – A Building Block For Pharmaceutical, R&D, https://www.indiaoppi.com/sites/default/files/PDF%20files/Regulatory%20DATA%20PR OTECTION%20-%20OPPI%20Position%20Paper.pdf (accessed on 7 October 2019).
- The WTO TRIPS / TRIPS Agreement.
- Di Masi J, Hansen R & Grabowski H, The price of innovation: New estimates of drug development costs, Journal of Health Economics, 22 (2003) 151–185.
- Clift C, Data protection and data-exclusivity in pharmaceuticals and agrochemicals, MIHR Oxford, (2007).
- Gopalakrishnan N S & Kadavan B, Study on Test Data Protection in India, 28 (2005).
- The new definition includes three categories of drugs where it is obligatory to provide data for approval. The first category is a new substance of chemical, which is not used in the country for a long period and which has not been recognized as effective and safe in the country. The second category is an approved drug with new indication, dosage or dosage form. The third category is a new combination of two or more already approved drugs or an existing combination with new indications, dosage or dosage form.
- Reddy S & Sandhu G S, Ministry of Chemicals & Fertilizers, Report on Steps to be taken by Government of India in the context of Data Protection Provisions of Article 39.3 of TRIPS, 11, 42 (2007), http://chemicals.nic.in/DPBooklet.pdf. If the drug is already approved in another country, Phase I and Phase II trials are not to be conducted again in India. Only Phase III or confirmatory trials are required to be conducted. Ragavan S, The significance of the data-exclusivity and its impact on generic drugs, Journal of Intellectual Property Studies, 1 (2017) 131, https://scholarship.law.tamu.edu/facscholar/816 (accessed on 2 October 2019).
- EC Report on Pharmaceutical Sector Inquiry (2009).
- Encouragement of New Clinical Drug Development: The Role of Data-exclusivity, https://www.who.int/intellectualproperty/topics/ip/en/DataExclusivity_2000.pdf (accessed on 28 September 2019).
- Clift C, Data Protection and Data-exclusivity in Pharmaceuticals and Agrochemicals, https://www.researchgate.net/publication/315070443 (accessed on 28 September 2019).
- For instance, in the United States only chemical entities never previously approved are entitled to exclusivity for a five-year period, but new uses or indications of an already approved entity are also entitled to exclusivity for three years.
- Dinca R, The “Bermuda Triangle” of Pharmaceutical Law, The Journal of World Intellectual Property, 5 (2005).
- Carlos M Correa, Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (Zed Books, Third Work Network, 2000).
- UNCTAD/ICTSD (N17) 530.
- Article 39, TRIPS Agreement, https://www.wto.org/english/docs_e/legal_e/27-trips_04d_e.htm (accessed on 28 September 2019).
- Ingo M & Mira B, Protection of Undisclosed Information Commentary of Article 39 of the Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS), (2014).
- Centre for WTO Studies, Indian Institute of Foreign Trade, Trade Secret Protection in India: The Policy Debate (2015), http://wtocentre.iift.ac.in/workingpaper/Trade%20Secret%20 Protection%20in%20India%20The%20policy%20debate.pdf (accessed on 28 September 2019).
- Friedman, D D, Landes W M & Posner R, Some Economics of Trade Secret Law, The Journal of Economic Perspectives, 5 (1) (1991) 61-72.
- Kumar A, Mohanty P & Nandakumar R, Legal protection of trade secrets: Towards a codified regime, Journal of Intellectual Property Rights, 11 (2006) 397-408, http://nopr.niscair.res.in/bitstream/123456789/3604/1/JIPR% 2011(6)%20397-408.pdf (accessed on 28 September 2019).
- MANU/DE/0891/2009, Syngenta India Ltd. v Union of India (UOI) (01.07.2009 - DELHC).
- Navigators Logistics Ltd. v Kashif Qureshi and Ors (2018) DLT 307.
- Pai V & Seetharaman R, Legal Protection of Trade Secrets (2004) 1 SCC (Jour) 22.
- Saltman Engineering Co v Campbell Engineering Co, (1948) 65 R.P.C. 203.
- Gorlin J, Encouragement of New Clinical Drug Development: The Role of Data-exclusivity, Fédération Internationale de l'Industrie du Médicament, Geneva (2000).
- Amin et al., The impact of Article 39.3 in India: A practical perspective, initiative for medicines, Access & Knowledge (2006).
- Correa C M, Trade Related Aspects of Intellectual Property Rights, Oxford University Press, (2007).
- UNCTAD/ITE, The TRIPS Agreement and Developing Countries, (1996) 48, http://www.unctad.org (assessed on 12 March 2014).
- UN Conference on Trade and Development, TRIPS Agreement and Developing Countries (UNCTAS/ITE/1) 48 (1996).
- Data-exclusivity, Encouraging development of New Medicines, International Federation of Pharmaceutical Manufacturers and Associations, June 2011, https://www.ifpma.org/wpcontent/uploads/2016/01/IFPMA_2011_Data_Exclusivity_ _En_Web.pdf.
- Bhatnagar J & Garg V, India: Data-exclusivity, http://www.mondaq.com/india/x/79418/Information+Securit y+Risk+Management/Data+Exclusivity (accessed on 1 October 2018).
- Kiruthika D, Data-exclusivity and Indian Law, http://journal.lawmantra.co.in/wpcontent/uploads/2015/09/5.pdf (accessed on 1 October 2019).
- Crystal J Chen, Patents v Data-exclusivity in pharmaceuticals, https://www.lexology.com/library/detail.aspx?g=5fe621cd-4372-49af-933f-714b3e8e7a02, (accessed on 1 October 2019).
- International Federation of Pharmaceuticals Manufacturers and Association, Data-exclusivity: Encouraging Development of New Medicines (2011), https://www.ifpma.org/wpcontent/uploads/2016/01/IFPMA_ 2011_Data_Exclusivity__En_Web.pdf (accessed on 1 October 2019).
- Mangan D, Mylan CEO Bresch said Company has learned from Epipen Furor, CNBC (10 January 2017), http://www.cnbc.com/2017/01/10/mylan-ceo-bresch-saidcompanyhas-learned-from-epipenfuror-hopes-trumpappreciatesdecisive-action-on-pricing-controversy.html; Campbell T, Pfizer Gets Back to Growth, The Motley Fool (9 February 2016), https://www.fool.com /investing/general/2016/02/09/pfizer-gets-back-to-growth.aspx (accessed on 1 October 2019).
- Declaration on the TRIPS Agreement and Public Health (2001), https://www.who.int/medicines/areas/policy/tripshealth.pdf (accessed on 01-10-2019)
- Basheer S, Protection of regulatory data under Article 39.3 of TRIPS: The Indian context. Intellectual Property Institute (IPI), Forthcoming, SSRN: https://ssrn.com/abstract=934269.
- Reddy S & Sandhu G S, Report on steps to be taken by Government of India in the context of data protection provisions of Article 39.3 of TRIPS Agreement. Delhi, (2007). 31 May 2007, http://chemicals.nic.in/DPBooklet.pdf.
- Shankar R, Health Ministry's nod to WHO for a study on data-exclusivity raises concern. PharmaBiz.com, (2009), 16 December 2009, http://www.gnaipr.com/Articles/Health%20Ministry%5c's%20nod%20to%20WHO%20for% 20a%20study%20on%20data%20exclusivity%20raises%20c oncern.pdf.
- Ragavan S, The significance of the data-exclusivity and its impact on generic drugs, Journal of Intellectual Property Studies, 1 (2017) 131, https://scholarship.law.tamu.edu/facscholar/816 (accessed on 2 October 2019).
- Encouragement of New Clinical Drug Development: The Role of Data-exclusivity, International Federation of Pharmaceutical Manufacturer’s Association, 2000, https://www.who.int/intellectualproperty/topics/ip/en/DataEx clusivity_2000.pdf.
- Prakash G, Data-exclusivity: A necessary Evil, Legal Service India, http://www.legalserviceindia.com/legal/article-135data-exclusivity-a-necessary-evil-.html.
- Jhaveri D, Detail Analysis of Law on Data-exclusivity – with Special Focus on India, http://jlsr.thelawbrigade.com/wpcontent/uploads/2017/06/Divyam-Jhaveri.pdf (accessed on 7 October 2019).
- Juan J R S, Love J & Weissman R, A Cost Sharing Model to Protect Investments in Phamaceutical Test Data, http://www.cptech.org (accessed on 6 April 2014).
- Free Trade Agreements (US-Colombia), http://www.ustr.gov (assessed on 7 April 2014).
- Roche Products v Bolar Pharmaceutical, 733 F.2d 858.
- Baker B K, A Critical Analysis of India’s DataExclusivity Provisions, www.healthgap.org (assessed on 6 April 2014).
- https://www.wto.org/english/thewto_e/minist_e/min01_e/mi ndecl_trips_e.htm, (accessed on 29 September 2018).
- http://dipp.nic.in/policies-rules-and-acts/policies/national-iprpolicy (accessed on 10 October 2018).
- http://164.100.158.44/index1.php?lang=1&level=1&sublinki d=6471&lid=4270 (accessed on 10 October 2018).
- http://apps.who.int/iris/bitstream/handle/10665/274331/Delhi -Declaration.pdf?sequence=5&isAllowed=y (accessed on 10 October 2018).
- Structural variability of Mycobacterium tuberculosis SSB and susceptibility to inhibition
Abstract Views :174 |
PDF Views:80
Authors
Srikalaivani Raja
1,
Anju Paul
1,
Sriram Raghavan
2,
Sibi Narayanan
3,
Somnath Shee
4,
Amit Singh
4,
Umesh Varshney
5,
Balasubramanian Gopal
1,
Mamannamana Vijayan
1
Affiliations
1 Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560 012, IN
2 Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560 012, India; Present address: RIKEN Center for Computational Science, JP
3 Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560 012, India; Present address: Sitaram Ayurveda Private Limited, Thrissur 680 007, IN
4 Department of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru 560 012, India; Centre for Infectious Disease Research, Indian Institute of Science, Bengaluru 560 012, IN
5 Department of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru 560 012, IN
1 Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560 012, IN
2 Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560 012, India; Present address: RIKEN Center for Computational Science, JP
3 Molecular Biophysics Unit, Indian Institute of Science, Bengaluru 560 012, India; Present address: Sitaram Ayurveda Private Limited, Thrissur 680 007, IN
4 Department of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru 560 012, India; Centre for Infectious Disease Research, Indian Institute of Science, Bengaluru 560 012, IN
5 Department of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru 560 012, IN
Source
Current Science, Vol 122, No 3 (2022), Pagination: 281-289Abstract
Single-stranded DNA is formed at various stages of DNA metabolism. It is protected from degradation by single-stranded DNA-binding proteins (SSBs). Structural variability has been observed in the quaternary arrangement of tetrameric SSBs from mycobacteria and other sources. Here we describe two novel crystal forms which illustrate the extent of structural variability. Docking studies carried out with inhibitors identified from DNA-binding assays allowed the characterization of eight distinct potential binding regions or grooves on each tetramer that circumvent structurally variable regions. Compounds known to inhibit certain bacterial SSBs were tested against Mycobacterium tuberculosis SSB (MtSSB) using DNA-binding and cellular assays. We report two compounds that inhibit MtSSB and growth of the bacterium. Together, this structural analysis reveals a strategy to exploit the variability of MtSSB for the design of inhibitors to this protein. The variability in structure of MtSSB could contribute to its susceptibility to inhibitionKeywords
Binding regions, crystal structure, docking, inhibitor development, Mycobacterium tuberculosis, structural plasticity.Full Text
References
- Chase, J. W. and Williams, K. R., Single-stranded DNA binding proteins required for DNA replication. Annu. Rev. Biochem., 1986, 55, 103–136.
- Lohman, T. M. and Ferrari, M. E., Escherichia coli singlestranded DNA-binding protein: multiple DNA-binding modes and cooperativities. Annu. Rev. Biochem., 1994, 63, 527–570.
- Shereda, R. D., Kozlov, A. G., Lohman, T. M., Cox, M. M. and Keck, J. L., SSB as an organizer/mobilizer of genome maintenance complexes. Crit. Rev. Biochem. Mol. Biol., 2008, 43(5), 289–318.
- Costes, A., Lecointe, F., McGovern, S., Quevillon-Cheruel, S. and Polard, P., The C-terminal domain of the bacterial SSB protein acts as a DNA maintenance hub at active chromosome replication forks. PLOS Genet., 2010, 6(12), e1001238.
- Terwilliger, T. C. et al., The TB structural genomics consortium: a resource for Mycobacterium tuberculosis biology. Tuberculosis, 2003, 83(4), 223–249.
- Vijayan, M., Structural biology of mycobacterial proteins: the Bangalore effort. Tuberculosis, 2005, 85(5), 357–366.
- Arora, A. et al., Structural biology of Mycobacterium tuberculosis proteins: the Indian efforts. Tuberculosis, 2011, 91(5), 456–468.
- Arcus, V. L., Lott, J. S., Johnston, J. M. and Baker, E. N., The potential impact of structural genomics on tuberculosis drug discovery. Drug Discov. Today, 2006, 11(1–2), 28–34.
- Raghunathan, S., Ricard, C. S., Lohman, T. M. and Waksman, G., Crystal structure of the homo-tetrameric DNA binding domain of Escherichia coli single-stranded DNA-binding protein determined by multiwavelength X-ray diffraction on the selenomethionyl protein at 2.9-A resolution. Proc. Natl. Acad. Sci. USA, 1997, 94(13), 6652–6657.
- Yang, C., Curth, U., Urbanke, C. and Kang, C., Crystal structure of human mitochondrial single-stranded DNA binding protein at 2.4 A resolution. Nature Struct. Biol., 1997, 4(2), 153–157.
- Saikrishnan, K. et al., Crystallization and preliminary X-ray studies of the single-stranded DNA-binding protein from Mycobacterium tuberculosis. Acta Crystallogr., Sect. D, 2002, 58(2), 327–329.
- Saikrishnan. K. et al., Structure of Mycobacterium smegmatis single-stranded DNA-binding protein and a comparative study involving homologus SSBs: biological implications of structural plasticity and variability in quaternary association. Acta Crystallogr. Sect. D, 2005, 61(8), 1140–1148.
- Kaushal, P. S., Singh, P., Sharma, A., Muniyappa, K. and Vijayan, M., X-ray and molecular-dynamics studies on Mycobacterium leprae single-stranded DNA-binding protein and comparison with other eubacterial SSB structures. Acta Crystallogr., Sect. D, 2010, 66(10), 1048–1058.
- Singh, A., Vijayan, M. and Varshney, U., Distinct properties of a hypoxia specific paralog of single stranded DNA binding (SSB) protein in mycobacteria. Tuberculosis, 2018, 108, 16–25.
- Arif, S. M. and Vijayan, M., Structural diversity based on variability in quaternary association. A case study involving eubacterial and related SSBs. Methods Mol. Biol., 2012, 922, 23–35.
- Voter, A. F., Killoran, M. P., Ananiev, G. E., Wildman, S. A., Hoffmann, F. M. and Keck, J. L., A high-throughput screening strategy to identify inhibitors of SSB protein–protein interactions in an academic screening facility. SLAS Discov., 2018, 23(1), 94– 101.
- Glanzer, J. G., Endres, J. L., Byrne, B. M., Liu, S., Bayles, K. W. and Oakley, G. G., Identification of inhibitors for single-stranded DNA-binding proteins in eubacteria. J. Antimicrob. Chemother., 2016, 71(12), 3432–3340.
- Huang, C. Y., Crystal structure of SSB complexed with inhibitor myricetin. Biochem. Biophys. Res. Commun., 2018, 504(4), 704– 708.
- Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R. and Leslie, A. G. W., iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. Sect. D, 2011, 67(4), 271–281.
- Winn, M. D. et al., Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. D, 2011, 67(4), 235–242.
- Matthews, B. W., Solvent content of protein crystals. J. Mol. Biol., 1968, 33(2), 491–497.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. and Read, R. J., Phaser crystallographic software. J. Appl. Crystallogr., 2007, 40(4), 658–674.
- Murshudov, G. N. et al., REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D, 2011, 67(4), 355–367.
- Emsley, P. and Cowtan, K., Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D, 2004, 60(12 and 1), 2126–2132.
- Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. and Sherman, W., Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des., 2013, 27(3), 221–234.
- Halgren, T. A., Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model., 2009, 49(2), 377–389.
- Friesner, R. A. et al., Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49(21), 6177–6196.
- Greenwood, J. R., Calkins, D., Sullivan, A. P. and Shelley, J. C., Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J. Comput. Aided Mol. Des., 2010, 24(6–7), 591–604.
- Cohen, G., ALIGN: a program to superimpose protein coordinates, accounting for insertions and deletions. J. Appl. Crystallogr., 1997, 30(6), 1160–1161.
- Hubbard, S. J. and Thornton, J. M., ‘NACCESS’, computer program. Department of Biochemistry and Molecular Biology, University College, London, UK, 1993.
- Pettersen, E. F. et al., UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25(13), 1605–1612.
- DeLano, W. L., PyMOL, 2002, http://www.pymol.org.
- Madeira, F. et al., The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res., 2019, 47(W1), W636–W641.
- Robert, X. and Gouet, P., Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res., 2014, 42(W1), W320–W324.
- Kuriata, A. et al., CABS-flex 2.0: a web server for fast simulations of flexibility of protein structures. Nucleic Acids Res., 2018, 46(W1), W338–W343.
- Saikrishnan, K. et al., Structure of Mycobacterium tuberculosis single-stranded DNA-binding protein. Variability in quaternary structure and its implications. J. Mol. Biol., 2003, 331(2), 385–393.
- Dubiel, K. et al., Structural mechanisms of cooperative DNA binding by bacterial single-stranded DNA-binding proteins. J. Mol. Biol., 2019, 431(2), 178–195.
- Waldman, V. M., Weiland, E., Kozlov, A. G. and Lohman, T. M., Is a fully wrapped SSB-DNA complex essential for Escherichia coli survival? Nucleic Acids Res., 2016, 44(9), 4317–4329.
- Revolutionary Changes in Traditional Drawing Tools : A Literature Review
Abstract Views :130 |
PDF Views:0
Authors
Affiliations
1 Department of Mass Communication, SMFE, Sharda University, Greater Noida, Uttar Pradesh, IN
2 Department of Physiotherapy, SAHS, Sharda University, Greater Noida, Uttar Pradesh, IN
1 Department of Mass Communication, SMFE, Sharda University, Greater Noida, Uttar Pradesh, IN
2 Department of Physiotherapy, SAHS, Sharda University, Greater Noida, Uttar Pradesh, IN
Source
Journal of Scientific and Technical Research (Sharda University, Noida), Vol 11, No 1 (2021), Pagination: 40-42Abstract
First thing that springs to mind whenever we think of drawing and sketching is a wooden stick called a graphite pencil. It was in 1795 that the Graphite Pencil made its debut. Graphite pencils have been around since the 18th century and are currently going strong in the 21st century. We all know that even in the 21st century, we cannot ignore the pencil’s presence and significance. We were taught how to write and draw by the pencil from the very first day of school.
Artists have long sought for new art forms, materials, techniques, and instruments. Because everything is moving so quickly in the digital age, artists are also looking for rapid and time-efficient results in their artwork. Thanks to improved technology, artists now have a better digital drawing tool. Using a digital drawing tool is quite comparable to using a traditional drawing pencil in the traditional sense.
In this post, we’ll take a look at several cutting-edge digital drawing tools and explain how they might benefit artists.
Keywords
I-Pad and Cintiq, Pen Tablet, Stylus in Mobile, Traditional Drawing Tool.References
- N. Y. W. Cheng, and S. Lane-Cumming, “Teaching with digital sketches,” in Design Communication Association’s 11th Biannual Conference, Jan. 2004, pp. 1-9.
- M. Sun, X. Cao, H. Song, S. Izadi, H. Benko, F. Guimbretiere, X. Ren, and K. Hinckley, “Enhancing naturalness of pen-and-tablet drawing through context sensing,” in Proceedings of the ACM International Conference on Interactive Tabletops and Surfaces, Nov. 2011, pp. 83-86.
- S. Mizuno, D. Kobayashi, M. Okada, J. I. Toriwaki, and S. Yamamoto, “Carving, painting, and printing with a pen tablet,” in Eurographics (Short Presentations), 2005, pp. 21-24.
- N. Y. W. Cheng, and A. McKelvey, “Learning design with digital sketching,” in Computer Aided Architectural Design Futures 2005, Springer, Dordrecht¸ 2005, pp. 291-300.
- N. Souleles, “iPad versus traditional tools in art and design: A complementary association,” British Journal of Educational Technology, vol. 48, no. 2, pp. 586-597, 2017.
- M. D. Carey, and S. Moucha, Illustrating/Writing Graphic Novels: Going Completely Digital. 2012.
- M. Nijboer, M. Gerl, and T. Isenberg, “Interaction concepts for digital concept sketching,” in Poster Presentations of the Seventh International Symposium on Non-Photorealistic Animation and Rendering, NPAR, New Orleans, USA, 2009.